- Oops!Something went wrong.Please try again later.
Sanofi will also pay Amunix up to $225 million based on certain future development milestones.
"We are excited to advance Amunix's promising pipeline rapidly and to combine their innovative candidate medicines with complementary molecules in Sanofi's immuno-oncology portfolio," said John Reed, global head of research and development at Sanofi.
Amunix's pipeline, which includes lead candidate AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi's focus on developing therapies in immuno-oncology.
Sanofi expects to complete the acquisition in Q1 of 2022.
Price Action: SNY shares are up 0.61% at $49.27 during the premarket session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.